Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Causes of death and re-hospitalization in cardiogenic shock.
Jeger RV, Assmann SF, Yehudai L, Ramanathan K, Farkouh ME, Hochman JS. Jeger RV, et al. Among authors: farkouh me. Acute Card Care. 2007;9(1):25-33. doi: 10.1080/17482940601178039. Acute Card Care. 2007. PMID: 17453536 Clinical Trial.
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
Dzavík V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Dzavík V, et al. Among authors: farkouh me. Eur Heart J. 2007 May;28(9):1109-16. doi: 10.1093/eurheartj/ehm075. Epub 2007 Apr 25. Eur Heart J. 2007. PMID: 17459901 Clinical Trial.
Long-term outcomes in non-diabetic patients with metabolic syndrome undergoing revascularization for multi-vessel coronary artery disease.
Yatskar L, Holper E, Bansilal S, Schwartzbard A, Lombardero M, Ramanathan K, Feit F, Fisher E, Faxon D, Hochman JS, Farkouh ME; BARI Investigators. Yatskar L, et al. Among authors: farkouh me. Atherosclerosis. 2008 Jun;198(2):389-95. doi: 10.1016/j.atherosclerosis.2007.09.046. Epub 2007 Dec 3. Atherosclerosis. 2008. PMID: 18061192 Clinical Trial.
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Am Heart J. 2008 Sep;156(3):528-536, 536.e1-5. doi: 10.1016/j.ahj.2008.05.015. Epub 2008 Jul 31. Am Heart J. 2008. PMID: 18760137 Free PMC article. Clinical Trial.
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
BARI 2D Study Group; Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. BARI 2D Study Group, et al. N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7. N Engl J Med. 2009. PMID: 19502645 Free PMC article. Clinical Trial.
Lumiracoxib, a highly selective COX-2 inhibitor.
Jeger RV, Greenberg JD, Ramanathan K, Farkouh ME. Jeger RV, et al. Among authors: farkouh me. Expert Rev Clin Immunol. 2005 May;1(1):37-45. doi: 10.1586/1744666X.1.1.37. Expert Rev Clin Immunol. 2005. PMID: 20477653
391 results